MetLife Investment Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

MetLife Investment Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-18,318	Closed	-$1.97M	–	3016
2023 Q1	$1.97M	Hold	18,318	–	–	0.01%	917
2022 Q4	$2.01M	Buy	18,318 +854	+5%	+$55.4K	0.02%	894
2022 Q3	$1.03M	Hold	17,464	–	–	0.01%	1173
2022 Q2	$493K	Hold	17,464	–	–	﹤0.01%	1674
2022 Q1	$659K	Buy	17,464 +6,227	+55%	+$246K	﹤0.01%	1608
2021 Q4	$444K	Buy	11,237 +6,326	+129%	+$198K	﹤0.01%	1572
2021 Q3	$116K	Buy	+4,911	New	+$116K	﹤0.01%	2373

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

MetLife Investment Management's RXDX Position: Q2 2023 in Review

MetLife Investment Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 18,318 shares — an estimated $1.97M sold.

MetLife Investment Management first reported a position in RXDX in Q3 2021 and held it in 7 quarters. The position peaked at $2.01M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

MetLife Investment Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
MetLife Investment Management sold 18,318 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.97M.
MetLife Investment Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
MetLife Investment Management's Prometheus Biosciences, Inc. Common Stock position peaked at $2.01M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on MetLife Investment Management's 13F filing for Q2 2023, filed 10 Aug 2023.